Back to Search
Start Over
LANADELUMAB SAFETY AND IMMUNOGENICITY: RESULTS FROM THE PHASE 3 HELP STUDY
- Source :
- Annals of Allergy, Asthma & Immunology; November 2018, Vol. 121 Issue: 5, Number 5 Supplement 1 pS36-S36, 1p
- Publication Year :
- 2018
-
Abstract
- Lanadelumab, a fully human monoclonal antibody targeting plasma kallikrein, effectively prevented attacks in patients with hereditary angioedema (HAE) in the phase 3 HELP Study (NCT02586805).
Details
- Language :
- English
- ISSN :
- 10811206
- Volume :
- 121
- Issue :
- 5, Number 5 Supplement 1
- Database :
- Supplemental Index
- Journal :
- Annals of Allergy, Asthma & Immunology
- Publication Type :
- Periodical
- Accession number :
- ejs47118857
- Full Text :
- https://doi.org/10.1016/j.anai.2018.09.114